Obviously, there is a lot of opportunity to tweak the dosing any way we wish in order to get that profile down even better than it is right now.Īnd as I mentioned before, Jonathan, we think we can get that to - without adjusting the dose titration by simply allowing for dose reduction in future trials. And again, the 1.8% was given without dose titration and still achieved a 9.4% weight loss at that point in time, which was as good as semaglutide at the same time point when you look at it on a placebo-adjusted basis. Remember that at the 1.2 milligram and 1.8 milligram doses, the adverse event rates leading to discontinuation were low. And the fact that we can achieve comparable safety and tolerability is really - it’s a complement to the drugs, and we believe that arises from the pharmacokinetics of pemvidutide with a slow entry into the bloodstream.

So we have to point out that any tolerability data that’s been generated to date has been in the absence of dose titration. I think that would be helpful to hear? Thanks. How do you think about an acceptable tolerability profile then in the upcoming little readout given the kind of tweaks Scot, you just discussed you could make going into Phase 3? And then can you also discuss the differentiation from pemvi to the other GLP-1 glucagon dual agonist, Merck and BI compound, either structurally or even from the data we’ve seen, we’ve gotten pretty good datasets from all three at this point. I want to follow-up from an earlier question. Questions or comments about this article and/or author? Click here>Įach was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2023. But these were not exactly blowout surprises, which investors come to expect from a company trading +85% year to date. Palo Alto Networks PANW also fell -9% in after-hours trading following its fiscal Q1 report this afternoon, even as it beat bottom-line expectations - earnings of $1.38 per share easily took out the $1.16 analysts were looking for, and a very healthy +66% growth year over year - as well as top-line - $1.90 billion versus $1.84 billion anticipated - and raised guidance for both earnings and revenues. Consider these good quarterly Q1 figures as having pulled forward some of the enterprise network giant’s sales. But next-quarter revenue guidance was taken way down: to a range of $12.6-12.8 billion the Zacks consensus had been for $14.15 billion.

Earnings of $1.11 per share outperformed the Zacks consensus by 8 cents - though Cisco never misses on its bottom line - on $14.7 billion in quarterly sales which surpassed the $14.61 billion expected, +8% year over year. There’s still a 2024 recession to consider, after all.Ĭisco Systems CSCO shares are down -9% following its earnings and revenue beats for fiscal Q1 after today’s close. Surely these levels were oversold a couple weeks ago, but the question becomes whether or not this news can sustain a further bullish push into the new year. Why would this be? Consider that, off late-October lows, the Nasdaq is up another +10.7%, the Russell is +9.4%, the S&P +8.8% and the Dow +7.5%. But as far as driving markets further up? That appetite seems to have gotten quenched. These are good “soft landing” numbers for the economy, in addition to coming close to claiming victory over inflation (though the Fed will likely not be voicing this anytime soon). Yesterday was a hard act to follow plenty of exuberance over peak interest rate levels has given away to something else today.Īhead of regular trading, PPI numbers for October were surprisingly low, finally obtaining a “2-handle” on year-over-year core to +2.9%, while Retail Sales for last month were slightly negative and Empire State for this month surprisingly stronger than expected.

The S&P 500 and the small-cap Russell 2000 split the difference, both +0.16% on the day. The Nasdaq lagged the other major indices for the session, even dipping negative for a short time but ultimately finishing +0.07%. Markets flattened out today by the closing bell, save the blue-chip Dow, which upturned slightly and closed +163 points, or +0.47%.

Nasdaq alt